Member Info for Moneymunch

Eric confirms they're ready to iniate the dog trial , " a program with possible reward at a very short time, with proof of concept much faster than in human and within a year could reach some interesting collaboration with a large Vet Pharma Company." ...Gla ;-)

Cheers Northeast, I was hoping we'd kick on from 3p plus, but hopefully not too long before we do, with more news from Eric in the pipeline, including the high chance of confirmation of finance/funding from a Vet Partner for the dog trials, which would be huge...Gl ;-)

The same Prof Nir Barzilai from Sirtlabs as per link below. Gla :-)

Https://longevity.technology/news/sirt6-the-protein-that-talks-the-talk-and-walks-the-walk/

Could the approval of longevity drugs for dogs pave the way for human longevity drugs?

The possibility of extending dogs’ lives with longevity drugs has also raised the possibility that scientists might be able to find drugs with the same life-extending effects in people. Dogs are actually known to be very good models for human aging – far better than mice models, in fact.

Nir Barzilai, professor of genetics and medicine at the Albert Einstein College of Medicine in New York, explained in an interview with The Guardian, that this is because they “share our environment in such a respect that their microbiota is more similar to their owners than to other dogs.” Essentially, we eat similar foods and follow a similar lifestyle, plus our metabolisms work in much the same way, and we suffer the same diseases, such as cancer and cognitive decline.

Many longevity biotech companies are already on the case when it comes to developing anti-aging drugs for humans. However, they are yet to be proven in a clinical setting. If longevity drugs for dogs could help speed up the development of human anti-aging drugs, then the approval of Loyal’s candidates could be even more of a milestone achievement.

hTtps://www.labiotech.eu/in-depth/longevity-drugs-for-dogs/

Upcoming - happening or appearing soon : forthcoming, approaching.

Every chance Porter, Genflow's Product Pipeline on their website states "Pivotal Trial Anti-aging for Dogs with Vet Partner", and as Eric stated today "it's upcoming clinical dog trial", suggests they might have a partner in place if the clinical trial is "upcoming "!!!??? Gl.:-)

https://genflowbio.com/science/product-pipeline/

Dog Longevity Startup Loyal Secures $45 Million in Funding

The San Francisco company is one of several longevity startups attracting the attention of venture-capital investors

March 21, 2024

Biotech startup Loyal has raised $45 million in equity to help bring its first longevity drug for dogs to market.

htTps://www.wsj.com/articles/dog-longevity-startup-loyal-secures-45-million-in-funding-23d85cf1

Ditto Porter, very positive and encouraging and great to hear the dog trials are back in focus, which must have a very high chance of attracting a JV partner from the Major players within the veterinary and canine world. Gl :-)

Great news for todays AGM.....Gla holders ;-)

RNS Number : 0280U

Genflow Biosciences PLC

27 June 2024

27 June 2024

Genflow Biosciences Plc

Genflow Biosciences Strengthens Pre-Clinical Efforts

with FDA Guidance and CDMO and CRO Selection

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to report advancements in its pre-clinical programs.

Genflow has initiated a feasibility study with a Contract Development Manufacturing Organization (CDMO), Exothera S.A, to assess the ability to produce its future MASH clinical lot in accordance with Good Manufacturing Practices (GMP).

Genflow is also in the process of selecting Contract Research Organizations (CROs) to conduct its upcoming dog clinical trial, aimed at studying its promising drug candidate, GF-1004. The Company is currently evaluating requests for proposals (RFPs) and is working diligently to finalize a definitive agreement next month.

In addition, Genflow has received research guidance from the FDA's Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT). The Company submitted a comprehensive briefing package detailing all preclinical (in vitro and in vivo) studies conducted with its lead drug candidate, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH).

The FDA has encouraged Genflow to proceed with its plans to identify appropriate animal models through pilot proof-of-concept (POC) studies. These studies will inform the definitive POC, toxicology, and biodistribution studies necessary for eventual clinical trials. Detailed summaries of the products used in each animal study and their comparability to the intended clinical product are to be included.

Dr. Eric Leire, CEO of Genflow commented: " We are excited by the momentum we have built in moving forward with our pre-clinical programs and the guidance received from the FDA. This encouragement reinforces our commitment to developing effective therapeutic solutions for age-related diseases. As we move forward with our dog clinical trials, we remain focused on our mission to improve healthspan."

For markets: Betting on biotech's bounce back.

The investment in Formation Bio signals a broader recovery in the biotech sector. With inflationary pressures easing and confidence building in the US economy's smooth descent, investors are flocking back to biotech, anticipating innovative breakthroughs. This trend suggests a revitalization of venture capital flow into biotech firms, supported by promising trial data and advanced AI applications. Investors should keep an eye on these developments for potential growth opportunities.

hTtps://finimize.com/content/formation-bio-secures-372-million-with-major-pharma-backing

Biotech megadeals: Exploring the surge in $100M+ deals

June 26, 2024

htTps://www.labiotech.eu/in-depth/biotech-megadeals/

In Eric we trust, big news stacking UP!!! Gl :-)

Publication Number WO/2024/121363

Publication Date 13.06.2024

International Application No. PCT/EP2023/084840

International Filing Date 08.12.2023

Another ( latest ) patent application. Gla ;-)

3.WO/2024/121363

VARIANTS OF SIRTUIN 6 FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE

WO - 13.06.2024

Int.Class A61K 38/43 Appl.No PCT/EP2023/084840 Applicant GENFLOW BIOSCIENCES SRL Inventor VINCIGUERRA, Manlio

The present invention relates to variants of sirtuin 6 for the treatment of non-alcoholic fatty liver disease.

htTps://patentscope.wipo.int/search/en/result.jsf?_vid=P21-LXVWW2-83046

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,651 followers

2h

A recent survey reveals that many Americans prefer a shorter, healthier life over a longer one burdened by diseases that impact their quality of life. But what if modern medicine could offer both longevity and health?

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s dedicated team of experienced researchers is at the forefront of the medical industry, working tirelessly to turn this possibility into a reality. We are committed to developing solutions that promise a longer and healthier life for everyone.

Read more here: hTtps://loom.ly/mbv6qjI

#GENF #aging #healthspan #longevity

Looks like share accumulation on the cheap...they want your shares imho... Big news at anytime and the next UPdate must be very close. Gla holders. :-)

Lol, definitely not, nothing more than impatient pi's who very likely are going to miss out on the next significant rise as positive news is delivered. In Eric we trust!!! Gla holders, not many things go up in a straight line and so hold on tight and enjoy the ride...Big news could drop at anytime. :-)

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,643 followers

6h

While advanced anti-aging treatments are on the horizon, The Economist has researched ways humans can extend their #healthspan presently. Italian scientist Valter Longo has sworn by fasting for years after learning about its benefits during his time at the USC Longevity Institute.

While lifestyle choices significantly impact #longevity, emerging treatments also promise enhanced and extended quality of life.

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) works with the #centenarian variant of the #SIRT6 gene, which has been correlated with a longer lifespan. This groundbreaking work has the potential to revolutionize how we treat a number of aging related diseases.

Read the article here: htTtps://loom.ly/Ho08u7w

#longevity #aging #GENF